Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1489-1494

  Van Hal, Sebastian J ^a,b   Wehrhahn, Michael C ^a   Barbagiannakos, Thelma ^a   Mercer, Joanne ^a   Chen, Dehua ^a   Paterson, David L ^c   Gosbell, Iain B ^a,b  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANALYTIC METHOD; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BROTH DILUTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EPSILOMETER TEST; FALSE POSITIVE RESULT; GLYCOPEPTIDE RESISTANCE DETECTION ETEST; GOLD STANDARD; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; MACROMETHOD ETEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARD VANCOMYCIN ESTEST; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; VITEK 2 TESTING;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; COST-BENEFIT ANALYSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

STAPHYLOCOCCUS AUREUS;

EID: 79953849777     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02302-10     Document Type: Article

References (27)

1. Adam, H. J., et al. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.
2. Ariza, J., et al. 1999. Vancomycin in surgical infections due to methicillinresistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. (Pubitemid 29219213)
3. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
4. Clinical Laboratory Standards Institute (CLSI). 2010. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI document M100-S20. CLSI, Wayne, PA.
5. Crobach, M. J., O. M. Dekkers, M. H. Wilcox, and E. J. Kuijper. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin. Microbiol. Infect. 15:1053-1066.
6. Cui, L., et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. (Pubitemid 36098547)
7. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
8. Hiramatsu, K., et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350: 1670-1673. (Pubitemid 28036828)
9. Horne, K. C., et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
10. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
11. Howden, B. P., P. D. Johnson, P. B. Ward, T. P. Stinear, and J. K. Davies. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047. (Pubitemid 44396410)
12. Leonard, S. N., K. L. Rossi, K. L. Newton, and M. J. Rybak. 2009. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63:489-492.
13. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
14. Musta, A. C., et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
15. Neoh, H. M., et al. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6:13.
16. Rybak, M. J., et al. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
17. Satola, S. W., M. M. Farley, K. F. Anderson, and J. B. Patel. 2011. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J. Clin. Microbiol. 49:177-183.
18. Sun, W., et al. 2009. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob. Agents Chemother. 53:3642-3649.
19. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. (Pubitemid 46651246)
20. van Hal, S. J., and D. L. Paterson. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
21. van Hal, S. J., D. L. Paterson, and I. B. Gosbell. 2010. The presence of vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus bloodstream infections is not associated with increased mortality, abstr. D-157, p. 10. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA. American Society for Microbiology, Washington, DC.
22. Voss, A., et al. 2007. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann. Clin. Microbiol. Antimicrob. 6:9.
23. Walsh, T. R., et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444. (Pubitemid 32606216)
24. Ward, P. B., P. D. Johnson, E. A. Grabsch, B. C. Mayall, and M. L. Grayson. 2001. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. 175:480-483. (Pubitemid 33039860)
25. Wootton, M., et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. (Pubitemid 32303403)
26. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
27. Yusof, A., et al. 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46:3042-3047.